When to Stop

• No documented kidney harm in healthy adults — same as for baseline creatine. The creatinine elevation is a measurement artifact (creatine → creatinine metabolism), not actual renal damage. Cystatin C-based eGFR shows no impairment. Pre-existing kidney disease (CKD stage 3+) is the one population where high-dose acute creatine should be cleared with nephrology first. Not relevant for users in this archetype.
• Severe GI distress at 25-30 g single dose without splitting / hot water / food — not dangerous, just unpleasant. Splitting eliminates this in nearly all cases.
• Hyponatremia risk only with extreme over-hydration during loading — drink to thirst, not to a fixed schedule.
• First time using the protocol: Try at 20 g (not 30 g) on a low-stakes evening to calibrate GI tolerability before relying on it for a high-stakes window. If 20 g is fine, scale to body-weight dose for subsequent uses.
• June 2026 bloodwork: if the acute protocol has been used within 24 hr of draw, creatinine will be transiently elevated. Tell the lab; cystatin C is the cleaner kidney function marker. Same caveat as for users in this archetype's chronic baseline use.
• 20 g/day × 5-7 days (loading) is well-tolerated; this is the same dose Gordji-Nejad used acutely.
• 20 g/day chronic for >30 days has limited human data in healthy adults but no signal of harm in trials that have done it.
• Highest tested chronic dose: 30 g/day for 5 years in ALS trials — no renal or hepatic signal. Very safe ceiling.
• For non-clinical recreational use: ceiling for daily-driver use is reasonably 10 g/day; pre-stress acute single dose 20 g is fine occasionally; chronic 20 g/day should be reserved for specific protocols with monitoring.